NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: CAPLIPOINT · data 2026-10-30
Caplin Point Laboratories Limited
In plain words
Price: 22.2% below its 52-week high of ₹2,990.
Delivery: 46.2% of traded shares were kept for delivery over the last 10 sessions, against 41.0% over the last 60.
Latest results: a net profit of ₹177 cr for the quarter ended Jun 2026 (+15.8% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,287 cr |
| Net profit (last 12 months) | ₹665 cr |
| Sales growth, 3 years (yearly) | 14.3% |
| Profit growth, 3 years (yearly) | 19.4% |
Latest results in brief (Q1 FY27)
CAPLIPOINT Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹610.36 crore, up 19.6% YoY and up 1.7% QoQ.
Net profit was ₹176.91 crore, up 15.8% YoY and up 4% QoQ.
Operating margin was 35% (34.8% a year ago).
EPS was ₹23.27, up 15.8% YoY and up 4% QoQ.
CAPLIPOINT के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹610.36 करोड़; पिछले साल की तुलना में 19.6% की बढ़त, पिछली तिमाही की तुलना में 1.7% की बढ़त।
शुद्ध मुनाफ़ा: ₹176.91 करोड़; पिछले साल की तुलना में 15.8% की बढ़त, पिछली तिमाही की तुलना में 4% की बढ़त।
ऑपरेटिंग मार्जिन: 35% (एक साल पहले 34.8%)।
EPS: ₹23.27; पिछले साल की तुलना में 15.8% की बढ़त, पिछली तिमाही की तुलना में 4% की बढ़त।
CAPLIPOINTના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹610.36 કરોડ; ગયા વર્ષની સરખામણીએ 19.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.7% વધારો.
ચોખ્ખો નફો: ₹176.91 કરોડ; ગયા વર્ષની સરખામણીએ 15.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4% વધારો.
ઓપરેટિંગ માર્જિન: 35% (એક વર્ષ પહેલાં 34.8%).
EPS: ₹23.27; ગયા વર્ષની સરખામણીએ 15.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
17/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 43.0% over the last 20 sessions vs 26.3% in the 40 before (1.63x); shares delivered per day 0.81x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 2/15: 2 schemes hold it, about ₹7 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 18 Sept 26Dividend Dividend ₹4 (ex-date) +6.2% next session
- 12 Aug 26Results Q1 FY27 results: profit +15.8% YoY -4.9% next session
- 29 May 26Dividend Dividend ₹4 (ex-date) -1.2% next session
- 14 May 26Results Q4 FY26 results: profit +20.8% YoY +8.5% next session
- 5 Feb 26Results Q3 FY26 results: profit +17.9% YoY -4.4% next session
- 5 Nov 25Results Q2 FY26 results: profit +18.1% YoY +0.5% next session
- 12 Sept 25Dividend Dividend ₹3 (ex-date) +1.6% next session
- 7 Aug 25Results Q1 FY26 results: profit +23.3% YoY +9.4% next session
- 30 May 25Dividend Dividend ₹3 (ex-date) -0.1% next session
- 15 May 25Results Q4 FY25 results: profit +15.8% YoY -0.3% next session
- 7 Feb 25Results Q3 FY25 results: profit +18.6% YoY -2.6% next session
- 8 Nov 24Results Q2 FY25 results: profit +13.9% YoY -5.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹610 cr | ₹177 cr | +15.8% | 35.0% | 23.27 |
| Mar 2026 | ₹600 cr | ₹170 cr | +20.8% | 34.0% | 22.38 |
| Dec 2025 | ₹543 cr | ₹164 cr | +17.9% | 34.9% | 21.56 |
| Sept 2025 | ₹534 cr | ₹154 cr | +18.1% | 35.4% | 20.32 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 70.57% | 70.57% | 70.57% | 70.57% |
| Foreign institutions (FII) | 5.73% | 5.75% | 6.15% | 6.59% |
| Domestic institutions (DII) | 2.20% | 2.49% | 2.14% | 2.05% |
| Mutual funds | 1.64% | 2.03% | 2.02% | 1.97% |
| Retail investors | 13.76% | 12.14% | 12.17% | 11.81% |
| Number of shareholders | 1,03,386 | 94,385 | 93,896 | 93,705 |
Common questions
What was Caplin Point Laboratories Limited's latest quarterly profit?
Caplin Point Laboratories Limited reported a net profit of ₹177 cr for the quarter ended Jun 2026 (+15.8% on the same quarter a year earlier), on revenue of ₹610 cr.
How much do promoters hold in Caplin Point Laboratories Limited?
Promoters held 70.57% of Caplin Point Laboratories Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Caplin Point Laboratories Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Caplin Point Laboratories Limited's P/E ratio?
About 26.7, based on the last 12 months' earnings and a price of ₹2,325.6 (data 2026-10-30).
What is the 52-week high and low of Caplin Point Laboratories Limited?
The 52-week high is ₹2,990 and the 52-week low is ₹1,500.3.
Mutual funds holding Caplin Point Laboratories Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 2 schemes holding about ₹7 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 0.71% | ₹7 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.40% | ₹0 cr |
Similar companies
Cohance Lifesciences Ltd (COHANCE) · Shilpa Medicare Limited (SHILPAMED) · OneSource Specialty Pharma Limited (ONESOURCE) · PFIZER LIMITED (PFIZER) · Alivus Life Sciences Ltd (ALIVUS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CAPLIPOINT in NSE Scanner →